Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment 5. Debunking Myths in the US Healthcare System
Top Ten Searches
aldosteronism contrast dialysis vitamin d bicarbonate arf amyloidosis hypocalcemia renal artery husYour Article Summary
See Latest ArticlesCost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma
Value in Health, 09/28/09
Hoyle M et al. – Temsirolimus has been shown to be clinically effective compared to interferon–alpha offering additional health benefits, however, with a cost per QALY in excess of £90,000, it may not be regarded as a cost–effective use of resources in some health care settings.
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
A Randomized Controlled Study of Weekly and Biweekly Dosing of Epoetin Alfa in CKD Patients With Anemia
Clinical Journal of the American Society of Nephrology, 11/05/09
Anemia and Erythrocytosis After Kidney Transplantation: A 5-Year Graft Function and Survival Analysis
Transplantation Proceedings, 11/11/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
Kidney International, 11/05/09
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
Article Search
Sponsor